Bibliography For Survodutide

Every Curated Peer-Reviewed Reference Indexed For This Compound. Each Citation Can Be Exported In BibTeX, RIS, EndNote, Or Plain Text.

Indexed Types:study

n.d. - study

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.

Unknown Authors.

n.d. - study

Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia.

Unknown Authors.

n.d. - study

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.

Unknown Authors.

n.d. - study

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.

Unknown Authors.

n.d. - study

Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy.

Unknown Authors.

n.d. - study

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.

Unknown Authors.

n.d. - study

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.

Unknown Authors.

n.d. - study

Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis.

Unknown Authors.

n.d. - study

Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.

Unknown Authors.

n.d. - study

Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.

Unknown Authors.

n.d. - study

Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence.

Unknown Authors.

n.d. - study

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

Unknown Authors.

n.d. - study

Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.

Unknown Authors.

n.d. - study

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.

Unknown Authors.

n.d. - study

Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.

Unknown Authors.

n.d. - study

Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.

Unknown Authors.

n.d. - study

Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH).

Unknown Authors.

n.d. - study

Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.

Unknown Authors.

n.d. - study

Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit With GLP-1/Glucagon Agonism.

Unknown Authors.

n.d. - study

Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.

Unknown Authors.

n.d. - study

Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic Syndrome Spectrum: A Narrative Review.

Unknown Authors.

n.d. - study

The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.

Unknown Authors.

n.d. - study

Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.

Unknown Authors.

n.d. - study

Future Directions in the Medical Treatment of Obesity: A Narrative Review.

Unknown Authors.

n.d. - study

Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis.

Unknown Authors.

n.d. - study

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Unknown Authors.

n.d. - study

Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.

Unknown Authors.

n.d. - study

Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.

Unknown Authors.

n.d. - study

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

Unknown Authors.

n.d. - study

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.

Unknown Authors.

n.d. - study

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Unknown Authors.

n.d. - study

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

Unknown Authors.

n.d. - study

Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics.

Unknown Authors.

n.d. - study

Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.

Unknown Authors.

n.d. - study

Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.

Unknown Authors.

n.d. - study

From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD.

Unknown Authors.

n.d. - study

Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.

Unknown Authors.

n.d. - study

A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.

Unknown Authors.

n.d. - study

Pharmacological management of obesity: Current landscape and emerging therapies.

Unknown Authors.

n.d. - study

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Unknown Authors.

n.d. - study

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.

Unknown Authors.

n.d. - study

Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.

Unknown Authors.

n.d. - study

The Evolution of Medications for Obesity Management.

Unknown Authors.

n.d. - study

Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice.

Unknown Authors.

n.d. - study

GLP-1 Medicines in Perspective: Approaches to Optimize Outcome.

Unknown Authors.

n.d. - study

Anti-Obesity Medications in Longevity and Aesthetic Medicine.

Unknown Authors.

n.d. - study

Beyond Weight Loss: Tirzepatide as a Metabolic Disease-Modifying Strategy for Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.

Unknown Authors.

n.d. - study

Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).

Unknown Authors.

n.d. - study

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.

Unknown Authors.

n.d. - study

Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.

Unknown Authors.

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.

Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia.

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.

Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy.

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.

Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis.

Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.

Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.

Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence.

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m&lt;sup&gt;2&lt;/sup&gt; in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.

Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.

Review: Special Issue: &lt;i&gt;Real-world evidence on the use of GLP1 receptor agonists&lt;/i&gt;: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.

Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH).

Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.

Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit With GLP-1/Glucagon Agonism.

Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.

Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic Syndrome Spectrum: A Narrative Review.

The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.

Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.

Future Directions in the Medical Treatment of Obesity: A Narrative Review.

Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis.

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.

Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics.

Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.

Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.

From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD.

Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.

A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.

Pharmacological management of obesity: Current landscape and emerging therapies.

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.

Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.

The Evolution of Medications for Obesity Management.

Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice.

GLP-1 Medicines in Perspective: Approaches to Optimize Outcome.

Anti-Obesity Medications in Longevity and Aesthetic Medicine.

Beyond Weight Loss: Tirzepatide as a Metabolic Disease-Modifying Strategy for Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.

Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.

Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.